269 related articles for article (PubMed ID: 27622336)
1. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
Guo ZQ; Zheng T; Chen B; Luo C; Ouyang S; Gong S; Li J; Mao LL; Lian F; Yang Y; Huang Y; Li L; Lu J; Zhang B; Zhou L; Ding H; Gao Z; Zhou L; Li G; Zhou R; Chen K; Liu J; Wen Y; Gong L; Ke Y; Yang SD; Qiu XB; Zhang N; Ren J; Zhong D; Yang CG; Liu J; Jiang H
Cancer Cell; 2016 Sep; 30(3):474-484. PubMed ID: 27622336
[TBL] [Abstract][Full Text] [Related]
2. Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.
Zheng T; Yang CG
Sci China Life Sci; 2017 Jan; 60(1):91-93. PubMed ID: 27888385
[No Abstract] [Full Text] [Related]
3. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
Li G; Ci W; Karmakar S; Chen K; Dhar R; Fan Z; Guo Z; Zhang J; Ke Y; Wang L; Zhuang M; Hu S; Li X; Zhou L; Li X; Calabrese MF; Watson ER; Prasad SM; Rinker-Schaeffer C; Eggener SE; Stricker T; Tian Y; Schulman BA; Liu J; White KP
Cancer Cell; 2014 Apr; 25(4):455-68. PubMed ID: 24656772
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship of SPOP Inhibitors against Kidney Cancer.
Dong Z; Wang Z; Guo ZQ; Gong S; Zhang T; Liu J; Luo C; Jiang H; Yang CG
J Med Chem; 2020 May; 63(9):4849-4866. PubMed ID: 32297747
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of SPOP protein in tumorigenesis and cancer therapy.
Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
[TBL] [Abstract][Full Text] [Related]
6. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
[TBL] [Abstract][Full Text] [Related]
7. Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma.
Chen Z; Li Z; Li C; Li B; Wang H; Nong D; Li X; Huang G; Lin J; Li W
BMC Cancer; 2022 Dec; 22(1):1277. PubMed ID: 36474188
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin ligase adaptor SPOP in cancer.
Cuneo MJ; Mittag T
FEBS J; 2019 Oct; 286(20):3946-3958. PubMed ID: 31495053
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
10. SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer.
Zeng C; Wang Y; Lu Q; Chen J; Zhang J; Liu T; Lv N; Luo S
J Exp Clin Cancer Res; 2014 Sep; 33(1):75. PubMed ID: 25204354
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.
Li C; Ao J; Fu J; Lee DF; Xu J; Lonard D; O'Malley BW
Oncogene; 2011 Oct; 30(42):4350-64. PubMed ID: 21577200
[TBL] [Abstract][Full Text] [Related]
12. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
[TBL] [Abstract][Full Text] [Related]
13. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
14. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
[TBL] [Abstract][Full Text] [Related]
15. The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells.
Lan X; Khandros E; Huang P; Peslak SA; Bhardwaj SK; Grevet JD; Abdulmalik O; Wang H; Keller CA; Giardine B; Baeza J; Duffner ER; El Demerdash O; Wu XS; Vakoc CR; Garcia BA; Hardison RC; Shi J; Blobel GA
Blood Adv; 2019 May; 3(10):1586-1597. PubMed ID: 31126914
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.
Liu J; Ghanim M; Xue L; Brown CD; Iossifov I; Angeletti C; Hua S; Nègre N; Ludwig M; Stricker T; Al-Ahmadie HA; Tretiakova M; Camp RL; Perera-Alberto M; Rimm DL; Xu T; Rzhetsky A; White KP
Science; 2009 Feb; 323(5918):1218-22. PubMed ID: 19164706
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of SPOP in Cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract][Full Text] [Related]
18. [Speckle-type POZ protein up-regulates c-Jun protein expression and promotes proliferation and invasion of renal carcinoma cells].
Wu L; Yu K; Cue Y; Zhu X; Yang Z; Ma J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):447-452. PubMed ID: 33849838
[TBL] [Abstract][Full Text] [Related]
19. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression.
Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW
EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168
[TBL] [Abstract][Full Text] [Related]
20. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
